Sat, Jan 24, 2015, 11:03 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • boxcarlong boxcarlong Jun 10, 2010 9:42 AM Flag

    Lets Do some MATH

    Yes I can agree on those numbers. I'am just being very very concervative on the patient population
    penetration rate ( based on 9M USA, 100M Worldwide) and the cost per patient to show how easy it will be to generate $1B in top-line sales for just ENDO. The cost to treat ENDO in the USA alone is $20B on an annual basis.

    The Elagolix partnership is going to be a significant game changer for NBIX. I don't think most investors have realized that. IMO, NBIX moves from a tier 4 biotech Co a Tier 2 co and tier 1 apon Elagolix FDA approval in Q4 FY13/ Q1 FY14. Than a follow on indication in FY15 for Uterin F.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NBIX
31.70+0.12(+0.38%)Jan 23 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Array BioPharma, Inc.
NASDAQFri, Jan 23, 2015 4:00 PM EST
Gran Tierra Energy, Inc.
AMEXFri, Jan 23, 2015 4:00 PM EST